Liver Endothelium Promotes HER3-Mediated Cell Survival in Colorectal Cancer with Wild-Type and Mutant KRAS

Overview

Journal Mol Cancer Res

Specialty Cell Biology

Date 2022 Mar 11

PMID 35276002

Authors

Moeez Rathore

Wei Zhang

Michelle Wright

Rajat Bhattacharya

Fan Fan

Ali Vaziri-Gohar

Jordan Winter

Zhenghe Wang

Sanford D Markowitz

Joseph Willis

Lee M Ellis

Rui Wang

Affiliations

Soon will be listed here.

Abstract

Implications: This body of work highlighted a potential strategy of using HER3 antibodies in combination with standard chemotherapy agents for treating patients with either KRAS wild-type or KRAS mutant metastatic colorectal cancer.

Citing Articles

Leucine-Rich Alpha-2-Glycoprotein 1 Promotes Metastatic Colorectal Cancer Growth Through Human Epidermal Growth Factor Receptor 3 Signaling.

Rathore M, Curry K, Huang W, Wright M, Martin D, Baek J Gastroenterology. 2024; 168(2):300-315.e3.

PMID: 39393543 PMC: 11769768. DOI: 10.1053/j.gastro.2024.10.004.

HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs.

Zeng H, Wang W, Zhang L, Lin Z Cancer Drug Resist. 2024; 7:14.

PMID: 38835349 PMC: 11149107. DOI: 10.20517/cdr.2024.11.

Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment.

Gmeiner W Cancers (Basel). 2024; 16(5).

PMID: 38473386 PMC: 10930828. DOI: 10.3390/cancers16051029.

HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma.

Desai O, Wang R Oncotarget. 2023; 14:439-443.

PMID: 37163206 PMC: 10171365. DOI: 10.18632/oncotarget.28421.

Liver Endothelium Microenvironment Promotes HER3-mediated Cell Growth in Pancreatic Ductal Adenocarcinoma.

Rathore M, Zhang W, Wright M, Zarei M, Vaziri-Gohar A, Hajihassani O J Cancer Sci Clin Ther. 2023; 6(4):431-445.

PMID: 36644317 PMC: 9838560. DOI: 10.26502/jcsct.5079182.

References

Sequist L, Gray J, Harb W, Lopez-Chavez A, Doebele R, Modiano M . Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. Oncologist. 2019; 24(8):1095-1102. PMC: 6693700. DOI: 10.1634/theoncologist.2018-0695. View

Lu J, Ye X, Fan F, Xia L, Bhattacharya R, Bellister S . Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell. 2013; 23(2):171-85. PMC: 3574187. DOI: 10.1016/j.ccr.2012.12.021. View

Wang R, Bhattacharya R, Ye X, Fan F, Boulbes D, Xia L . Endothelial cells activate the cancer stem cell-associated NANOGP8 pathway in colorectal cancer cells in a paracrine fashion. Mol Oncol. 2017; 11(8):1023-1034. PMC: 5537915. DOI: 10.1002/1878-0261.12071. View

Jonna S, Feldman R, Swensen J, Gatalica Z, Korn W, Borghaei H . Detection of NRG1 Gene Fusions in Solid Tumors. Clin Cancer Res. 2019; 25(16):4966-4972. PMC: 7470623. DOI: 10.1158/1078-0432.CCR-19-0160. View

Kakarla M, ChallaSivaKanaka S, Hayward S, Franco O . Race as a Contributor to Stromal Modulation of Tumor Progression. Cancers (Basel). 2021; 13(11). PMC: 8197868. DOI: 10.3390/cancers13112656. View

Schoeberl B, Faber A, Li D, Liang M, Crosby K, Onsum M . An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 2010; 70(6):2485-94. PMC: 2840205. DOI: 10.1158/0008-5472.CAN-09-3145. View

Wang R, Ye X, Bhattacharya R, Boulbes D, Fan F, Xia L . A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling. Stem Cells Transl Med. 2016; 5(3):331-8. PMC: 4807666. DOI: 10.5966/sctm.2015-0168. View

Cleary J, McRee A, Shapiro G, Tolaney S, ONeil B, Kearns J . A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan. Invest New Drugs. 2016; 35(1):68-78. DOI: 10.1007/s10637-016-0399-7. View

Michel M, Kaps L, Maderer A, Galle P, Moehler M . The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy. Cancers (Basel). 2021; 13(10). PMC: 8150459. DOI: 10.3390/cancers13102296. View

10.

Styczen H, Nagelmeier I, Beissbarth T, Nietert M, Homayounfar K, Sprenger T . HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer. Oncotarget. 2015; 6(17):15065-76. PMC: 4558136. DOI: 10.18632/oncotarget.3527. View

11.

Drilon A, Somwar R, Mangatt B, Edgren H, Desmeules P, Ruusulehto A . Response to ERBB3-Directed Targeted Therapy in -Rearranged Cancers. Cancer Discov. 2018; 8(6):686-695. PMC: 5984717. DOI: 10.1158/2159-8290.CD-17-1004. View

12.

Margalit O, Shacham-Shmueli E, Lawrence Y, Yang Y, Reiss K, Golan T . Lung Metastasis Predicts Better Prognosis in Metastatic Colorectal Cancer With Mutated KRAS. Clin Colorectal Cancer. 2019; 18(3):e300-e307. DOI: 10.1016/j.clcc.2019.06.001. View

13.

Kiavue N, Cabel L, Melaabi S, Bataillon G, Callens C, Lerebours F . ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. Oncogene. 2019; 39(3):487-502. DOI: 10.1038/s41388-019-1001-5. View

14.

Odintsov I, Lui A, Sisso W, Gladstone E, Liu Z, Delasos L . The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic Fusions. Clin Cancer Res. 2021; 27(11):3154-3166. PMC: 8172458. DOI: 10.1158/1078-0432.CCR-20-3605. View

15.

Liu J, Ray-Coquard I, Selle F, Poveda A, Cibula D, Hirte H . Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. J Clin Oncol. 2016; 34(36):4345-4353. PMC: 5562430. DOI: 10.1200/JCO.2016.67.1891. View

16.

Cremolini C, Antoniotti C, Stein A, Bendell J, Gruenberger T, Rossini D . Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. J Clin Oncol. 2020; :JCO2001225. DOI: 10.1200/JCO.20.01225. View

17.

Watanabe S, Yonesaka K, Tanizaki J, Nonagase Y, Takegawa N, Haratani K . Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer. Cancer Med. 2019; 8(3):1258-1268. PMC: 6434202. DOI: 10.1002/cam4.1995. View

18.

Denlinger C, Keedy V, Moyo V, MacBeath G, Shapiro G . Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Invest New Drugs. 2021; 39(6):1604-1612. PMC: 8541959. DOI: 10.1007/s10637-021-01145-y. View

19.

Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H . Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science. 2009; 325(5947):1555-9. PMC: 2820374. DOI: 10.1126/science.1174229. View

20.

Ippen F, Alvarez-Breckenridge C, Kuter B, Fink A, Bihun I, Lastrapes M . The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in -Mutant Breast Cancer Brain Metastases. Clin Cancer Res. 2019; 25(11):3374-3383. PMC: 6685218. DOI: 10.1158/1078-0432.CCR-18-3049. View